Medicare Industry Update - New Alzheimer’s Drug Aduhelm

CMS Proposes Medicare Coverage Policy for Aduhelm for the treatment of Alzheimer’s Disease; which means the FDA-approved drug will be covered for people with Medicare, but only if they are enrolled in qualifying clinical trials.

For more information you can read the full CMS press release here.

Have questions about Aduhelm or how Medicare premiums could be affected? Call us at 800-268-2800.

Sources:

https://www.kff.org/policy-watch/medicares-coverage-decision-for-the-new-alzheimers-drug-and-why-it-matters/#:~:text=Back%20in%20November%202021%2C%20prior,Part%20B%20premium%20for%202022

https://www.cms.gov/newsroom/press-releases/cms-proposes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment

https://www.fiercehealthcare.com/payer/lawmakers-ratchet-up-pressure-cms-to-change-part-b-premiums-after-aduhelm-price-drop

Medicare Industry Update - New Alzheimer’s Drug Aduhelm

Sources:

Recent Posts

Scam Radar — April 2024

Devoted Health’s MA Plan to Come to More States in 2025

Find and Compare Medicare Providers Near You

Sidebar Setup

Agent Tools

The Company

Sign In

Your username is the email you registered with.